Placebo response is one of the most significant challenges faced by drug developers who are investigating new pain medications. According to a review of published chronic neuropathic pain trials, placebo responses have increased in magnitude over time, making it even more difficult to definitively demonstrate treatment advantage. Research has also shown that up to 60 percent of study participants may experience placebo-related analgesic responses and that these responses may be persistent.
O.C Suboxone understands the severity of opioid use disorder and is working to raise awareness on healthier alternatives to treat chronic pain.
The U.S. Food and Drug Administration approved Athena Bioscience LLC’s Qdolo (tramadol hydrochloride) Oral Solution 5mg/1mL C-IV, an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Acadia Pharmaceuticals is adding a novel pain portfolio to the company’s pipeline through the acquisition of Texas-based CerSci Therapeutics for $52.5 million.
With the opioid crisis gripping the United States, many doctors have been looking at alternate treatments to help patients with long-term chronic pain. A new study shows that the venom from a scorpion sting could provide a solution.
Former U.S. National Football League (NFL) athletes who bulked up before and during their professional careers have an increased risk of heart disease and other health problems compared with other players, researchers say.
A late-stage study for fasinumab conducted by Regeneron Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. hit the mark in assessing patients with chronic pain from osteoarthritis of the knee or hip.
DyAnsys Inc. announced that the U.S. Food and Drug Administration cleared the company’s auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.
During its second-quarter 2017 financial reporting, Egalet Corporation also announced it plans to cut the company’s non-sales staff by almost 40 percent.
Shares of pain-relief company Cara Therapeutics were up more than 16 percent after the company grabbed the Breakthrough Therapy Designation for its chronic kidney disease treatment CR845.